Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

BRCA1 and BRCA2 Mutations Yield Better Prognosis in Ovarian Cancer Patients

January 25th 2012

Patients with ovarian cancer who express BRCA1/2 mutations demonstrated a better overall survival after 5 years.

Dr. Birrer Discusses Recurrent Ovarian Cancer Treatment

January 23rd 2012

Dr. Michael Birrer, from Massaschusetts General Hospital Cancer Center, Discusses Recurrent Ovarian Cancer Treatment

Brain Metastasis Common in Ovarian Cancer

January 20th 2012

Half of all women with advanced ovarian cancer who develop brain cancer have a single metastasis to the brain.

Fertility Treatment Increases Risk of Ovarian Cancer

January 16th 2012

Subfertile women who undergo ovarian stimulation for in vitro fertilization have an increased risk of ovarian malignancies.

Avastin Increases PFS in Patients With Ovarian Cancer

December 29th 2011

Bevacizumab (Avastin) improved progression-free survival (PFS) in patients with ovarian cancer but was not shown to affect overall survival (OS), according to a new study...

Guidelines for Genetic Counseling or BRCA 1/2 Testing Are Often Ignored

October 25th 2011

Primary care physicians in the US adhere poorly to established guidelines for genetic counseling and testing for women who are at high risk of breast and ovarian cancer.

5 Abstracts Among SGO Highlights

September 30th 2011

This report highlights 5 abstracts relevant to the current and future management of patients with female pelvic malignancies.

ASCO 2011: What Nurses Need to Know

August 26th 2011

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

Bevacizumab Plus Chemotherapy May Improve Overall Survival In High-Risk Ovarian Cancer

August 2nd 2011

Concurrent and continued bevacizumab added to standard chemotherapy with carboplatin/ paclitaxel improved OS in women with high-risk ovarian cancer, according to an interim survival analysis of the ICON7 trial.

Judge Rules BRCA Genes Can Be Patented, Overturning Previous Decision

August 1st 2011

On July, 29, 2011, a US appeals court sided with Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes.

Novel Agent Demonstrates Activity in Heavily Pretreated Ovarian Cancer That Progressed on Pegylated Doxorubicin

August 1st 2011

A novel topoisomerase-I inhibitor designated NKTR-102 demonstrated clinically significant activity as a single agent in patients with heavily pretreated ovarian cancer who failed prior PLD.

Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer

July 27th 2011

Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in PFS when bevacizumab was added to chemotherapy and continued as maintenance therapy.

Dr. Vogelzang Discusses the Cabozantinib Trial Design

July 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design

Game-Changers: 11 Key Abstracts in ASCO Lineup

July 18th 2011

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Dr. Vogelzang Describes Cabozantinib's Side Effects

June 21st 2011

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Dr. Vogelzang on Cabozantinib Clinical Trial Results

June 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Studies Find That Talc-Based Powder Increases the Risk of Ovarian Cancer

June 17th 2011

Long-term use of talc-based powder significantly increased the risk of invasive ovarian cancer in a large case-control study

Diagnosing Ovarian Cancer: Does it matter when

June 10th 2011

More often than not, ovarian cancer is diagnosed at an advanced stage

NCCN's 16th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 24th 2011

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

Towards Personalized Medicine in Ovarian Cancer

May 19th 2011

The goal of personalized medicine remains in its infancy as oncologists strive to determine treatments specific to a patient's tumor characteristics